Elipovimab Biosimilar - Research Grade

Human

HIV-1

>1mg/ml

IgG1 - lambda2

CHO Cells

Lafuvitug Biosimilar - Research Grade (ICH5621), Suvizumab Biosimilar - Research Grade (ICH5890), Teropavimab Biosimilar - Research Grade (ICH5917), Zinlirvimab Biosimilar - Research Grade (ICH6009)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is an unconjugated, non-therapeutic research-grade analog of elipovimab (development code GS-9722), built around the same HIV-1 envelope target. It is a full-length human IgG1 with a lambda light chain, supplied for laboratory research use only (RUO) and is not a clinical drug. Elipovimab is a broadly neutralizing anti-HIV-1 antibody derived from the bNAb PGT121, which recognizes the V3-glycan supersite on the viral envelope. The originator molecule was engineered as an effector-function-enhanced antibody intended to both neutralize virus and promote clearance of HIV-infected cells, and was evaluated in early-phase clinical studies aimed at reducing the latent viral reservoir. As a research-grade biosimilar analog, this material is intended for in-vitro and functional characterization work rather than patient administration. It is produced to low-endotoxin research specifications and is available in bulk milligram-to-gram quantities to support assay standardization, comparator studies, and method development. Because the target is a viral antigen rather than a host protein, this reagent is typically used in binding, neutralization, and effector-function assays rather than in immune-cell modulation experiments. Elipovimab targets the HIV-1 envelope glycoprotein, specifically the V3-glycan (high-mannose patch) supersite on gp120, one of the recurrent sites of vulnerability recognized by broadly neutralizing antibodies. The HIV-1 envelope trimer (gp120/gp41) mediates receptor engagement (CD4 and coreceptor) and membrane fusion, and is the sole viral antigen exposed on the virion surface, making it the principal target for neutralizing humoral immunity. V3-glycan-directed antibodies such as the PGT121 lineage bind a composite epitope of the V3 base and surrounding N-linked glycans, blocking the conformational changes required for entry. Because envelope is heavily glycosylated and highly variable, broad neutralization requires recognition of conserved glycan-dependent features. Effector-enhanced Fc engineering additionally recruits Fc-gamma-receptor-bearing effector cells to kill infected cells expressing surface envelope.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Elipovimab (anti-HIV-1) Biosimilar

Q: Is the Elipovimab biosimilar available in bulk or gram quantities?

A: Yes — the Elipovimab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Elipovimab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Elipovimab biosimilar bind?

A: It is an unconjugated, non-therapeutic analog of Elipovimab that recognises HIV-1.